Amanote Research
Register
Sign In
Patient-Derived First Generation Xenografts of Non-Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-09-2878
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
February 23, 2010
Authors
X. Dong
J. Guan
J. C. English
J. Flint
J. Yee
K. Evans
N. Murray
C. MacAulay
R. T. Ng
P. W. Gout
W. L. Lam
J. Laskin
V. Ling
S. Lam
Y. Wang
Publisher
American Association for Cancer Research (AACR)
Related search
Comparison Between NOD/SCID Mice and BALB/c Mice for Patient-Derived Tumor Xenografts Model of Non-Small-Cell Lung Cancer
Cancer Management and Research
Oncology
Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine
Frontiers in Oncology
Cancer Research
Oncology
Palliative Chemotherapy for Advanced Non-Small Cell Lung Cancer
BMJ
Patient-Derived Breast Tumor Xenografts Facilitating Personalized Cancer Therapy
Breast Cancer Research
Cancer Research
Oncology
Oncologic Treatment of Non-Small Cell Lung Cancer Part B: Adjuvant Chemotherapy for Resected Non-Small Cell Lung Carcinoma
Chemotherapy for Non-Small Cell Lung Cancer in Elderly Patients
Chest
Cardiology
Critical Care
Cardiovascular Medicine
Intensive Care Medicine
Pulmonary
Respiratory Medicine
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Clinical Cancer Research
Cancer Research
Oncology
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
Phase II Study of Gemcitabine Plus Oxaliplatin as First-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
